CERT vs SLP
CERT: Certara provides the biosimulation software and AI-driven expertise that helps pharmaceutical companies simulate drug behavior in the body to accelerate development and increase approval success. SLP: Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences industry.
Side-by-side fundamentals
| Metric | CERT | SLP | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $8.64 | $18.50 | |
| Market cap | $1.3B | $374M | |
| P/E as of 2026-10-08 | n/a | 46.23 | |
| Net margin FY2025, SEC XBRL | -0.4% | -81.7% | CERT higher |
| Gross margin FY2025, SEC XBRL | n/a | +58.4% | |
| Operating margin FY2025, SEC XBRL | +5.0% | -89.3% | CERT higher |
| ROE FY2025, SEC XBRL | -0.2% | -51.9% | CERT higher |
| ROA FY2025, SEC XBRL | -0.1% | -49.1% | CERT higher |
| Debt / equity as of 2026-09-03 | 0.30 | 0.00 | SLP lower |
| Revenue growth (YoY) as of 2026-09-03 | +0.7% | +2.1% | SLP higher |
| Revenue CAGR (3y) SEC XBRL | +7.7% | +13.7% | SLP higher |
| Dividend yield as of 2026-09-02 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | 6 | SLP higher |
| Beta as of 2026-09-03 | 0.95 | 0.84 | |
| 1-year return as of 2026-10-08 close | -33.5% | +12.3% | SLP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.